
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    <title>CAS Newsletter</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
</head>
<body style="margin: 0; padding: 0;">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
    <tr>
        <td style="padding: 10px 0 30px 0;">
            <table align="center" border="0" cellpadding="0" cellspacing="0" width="600" style="border: 1px solid #cccccc; border-collapse: collapse;">
                <tr>
                    <td align="center" bgcolor="#ffffff" style="padding: 10px 0px 0px 0px; color: #ffffff; font-size: 28px; font-weight: bold; font-family: Arial, sans-serif;">
                        <a href="https://academic.oup.com/abt">
                            <img src="https://github.com/xinyu-dev/cas/blob/master/logos/news%20alert%20header.png?raw=True" alt="Logo" width="700" height="280">
                        </a>
                    </td>
                </tr>
                <tr>
                    <td bgcolor="#ffffff" style="padding: 30px 30px 40px 30px;">
                        <table border="0" cellpadding="0" cellspacing="0" width="100%">
                            <tr>
                                <td style="color: black; font-family: 'Trebuchet MS', sans-serif; padding: 6px 0px 6px 0px " align="center" bgcolor=#E5E7E9>
                                    <b>May 3, 2020</b>
                                </td>
                            </tr>
                            <tr>
                                <td style="color: #43729F; font-family: 'Trebuchet MS', sans-serif; font-size: 26px; padding: 30px 10px 30px 10px ">
                                    <b>Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy</b>
                                </td>
                            </tr>
                            <tr>
                                <td style="color:white; font-family: 'Trebuchet MS', sans-serif; font-size: 20px;padding: 10px 15px 10px 15px" bgcolor="43729f">
                                    <b>Editor's Note</b>
                                </td>
                            </tr>
                            <tr>
                                <td style="color:black; font-family: Geneva, sans-serif; font-size: 16px;padding: 30px 15px 30px 15px" bgcolor="d4f5ff">
                                    We are pleased to introduce a recent article published in Antibody Therapeutics, the official journal of Chinese Antibody Society, entitled “Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy”. It is the 2nd COVID-19 related article published in Antibody Therapeutics through the fast track review process which took only 8 days from submission to online publication. The following is the abstract of this research article.
                                </td>
                            </tr>
                            <tr>
                                <td style="color: #43729F; font-family: Arial, sans-serif; padding: 30px 10px 2px 10px " align="center">
                                    <img src="https://github.com/xinyu-dev/cas/blob/master/newsletter/journal/2020-05-03%20Article.png?raw=True" alt="article" width="640" height="400" style="display: block;" />
                                </td>
                            </tr>
                            <tr>
                                <td style="padding: 0px 0px 20px 0px; color: grey; font-family: Geneva, sans-serif; font-size: 16px;" align="center">
                                    <hr width="640">
                                    <p>Figure 1. Schematic presentation of a competitive biopanning strategy.</p>
                                    <p><a href="https://academic.oup.com/abt/advance-article/doi/10.1093/abt/tbaa008/5827124">Free access to full article</a></p>
                                </td>
                            </tr>

                            <tr>
                                <td style="padding: 10px 0 30px 0; color: black; font-family: Geneva, sans-serif; font-size: 16px; line-height: 20px;">
                                    <p>The infection of the novel coronavirus SARS-CoV-2 has caused more than 200,000 deaths, but no vaccine or therapeutic monoclonal antibody is currently available. SARS-CoV-2 relies on its spike protein, in particular the receptor binding domain (RBD), to bind human cell receptor angiotensin-converting enzyme 2 (ACE2) for viral entry, and thus targeting RBD holds the promise for preventing SARS-CoV-2 infection.</p>
                                    <p>In this work, a competitive biopanning strategy of a phage display antibody library was applied to screen blocking antibodies against RBD (see the Figure1 below). High-affinity antibodies were enriched after the first round using a standard panning process in which RBD-His was immobilized as a bait. At the next two rounds, immobilized ACE2-Fc and free RBD-His were mixed with the enriched phage antibodies. Antibodies binding to RBD at epitopes different from ACE2-binding site were captured by the immobilized ACE2-Fc, forming a “sandwich” complex. Only antibodies competed with ACE2 can bind to the free RBD-His in the supernatant and be subsequently separated by the Ni-NTA magnetic beads.</p>
                                    <p>Top 1  lead (rRBD-15) from the competitive biopanning of our synthetic antibody library, Lib AB1, was produced as the full-length IgG1 format. It was proved to competitively block the binding of RBD to ACE2 and potently inhibit SARS-CoV-2 pseudovirus infection with IC50 values of 12 nM. Nevertheless, top 1 lead (rRBD-16) from the standard biopanning can only bind to RBD in vitro, but not have the blocking or neutralization activity. Our strategy can efficiently isolate the blocking antibodies of RBD, and it would speed up the discovery of neutralizing antibodies against SARS-CoV-2.</p>

                                </td>
                            </tr>

                            <tr>
                                <td style="color:white; font-family: 'Trebuchet MS', sans-serif; font-size: 20px;padding: 10px 15px 10px 15px" bgcolor="43729f">
                                    <b>Call for Paper On COVID-19</b>
                                </td>
                            </tr>
                            <tr>
                                <td style="color:black; font-family: Geneva, sans-serif; font-size: 16px;padding: 30px 15px 30px 15px" bgcolor="d4f5ff">
                                    <p>
                                        Antibody Therapeutics is an official journal of the Chinese Antibody Society and published by the Oxford University Press. As a peer-reviewed and open access journal, Antibody Therapeutics provides a forum for the publication of the latest advances and challenges in the discovery, research, development and methodology of therapeutic antibodies for global scientific community.
                                    </p>

                                    <p>
                                        The current COVID-19 pandemic is an unprecedented global public health challenge. Antibody Therapeutics invites papers that contribute knowledge to develop therapeutics and diagnostics strategies for our battle against COVID-19. We are particularly interested in research, method or review articles regarding discovery and engineering of COVID-19 diagnostic and therapeutic antibodies for clinical applications. Given the urgency of the current global pandemic, we will provide a fast-track option for all COVID-19 manuscripts. It will take 2 weeks or less from submission to acceptance. Manuscripts should be submitted via Antibody Therapeutics online <a href="https://mc.manuscriptcentral.com/abt">submission site</a>. Authors can publish in the journal with no charge (see the <a href="https://academic.oup.com/abt/pages/General_Instructions">authors’ instructions</a>).
                                    </p>

                                    <p>
                                        Correspondence or questions: <a href="mailto:abt@oup.com">contact editorial office</a>
                                    </p>

                                    <p>
                                        Mitchell Ho, Editor-in-Chief
                                    </p>
                                    <p>
                                        Zhiqiang An , Deputy Editor-in-Chief
                                    </p>
                                </td>
                            </tr>

                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <hr>  <!--Horizontal Line Divider-->
                    </td>
                </tr>
                <tr>
                    <td bgcolor=white style="padding: 30px 30px 30px 30px;">
                        <table border="0" cellpadding="0" cellspacing="0" width="100%">
                            <tr>
                                <td style="color: #43729f; font-family: Arial, sans-serif; font-size: 14px;" width="75%">
                                    <p>&copy Chinese Antibody Society 2020. </p>
                                    <p>Follow us on Wechat: <b>chinese_antibody</b> or <a style="font:bold" href="https://chineseantibody.org/">visit website</a></p>
                                </td>
                                <td align="right" width="25%">
                                    <table border="0" cellpadding="0" cellspacing="0">
                                        <tr>
                                            <td style="font-family: Arial, sans-serif; font-size: 12px; font-weight: bold;">
                                                <img src="https://github.com/xinyu-dev/cas/blob/master/logos/wechat.png?raw=True" alt="Wechat" width="38" height="38" style="display: block;" border="0" />
                                            </td>
                                            <td style="font-size: 0; line-height: 0;" width="20">&nbsp;</td>
                                            <td style="font-family: Arial, sans-serif; font-size: 12px; font-weight: bold;">
                                                <a href="https://twitter.com/ChineseAntibody" style="color: #ffffff;">
                                                    <img src="https://github.com/xinyu-dev/cas/blob/master/logos/twitter.png?raw=True" alt="Twitter" width="38" height="38" style="display: block;" border="0" />
                                                </a>
                                            </td>
                                            <td style="font-size: 0; line-height: 0;" width="20">&nbsp;</td>
                                            <td style="font-family: Arial, sans-serif; font-size: 12px; font-weight: bold;">
                                                <a href="https://www.linkedin.com/company/chineseantibodysociety/" style="color: #ffffff;">
                                                    <img src="https://github.com/xinyu-dev/cas/blob/master/logos/linkedin.png?raw=True" alt="Linkedin" width="38" height="38" style="display: block;" border="0" />
                                                </a>
                                            </td>

                                        </tr>
                                    </table>
                                </td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </table>
        </td>
    </tr>
</table>
</body>
</html>
